Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives

Cancer Treat Rev. 2020 Aug:88:102030. doi: 10.1016/j.ctrv.2020.102030. Epub 2020 May 28.

Abstract

Gastrointestinal cancers include colorectal, gastric, oesophageal, pancreatic and liver cancers. They continue to be a significant cause of mortality and morbidity worldwide. Current treatment strategies include chemotherapy, surgery, radiotherapy and targeted therapies. Immunotherapy has recently been incorporated in treatment regimens for some gastrointestinal malignancies and research into different immune modifying treatments is being carried out in this context. Approaches to immune modulation such as vaccination, adoptive cell therapy and checkpoint inhibition have shown varying clinical benefit, with most of the benefit seen in checkpoint inhibition. This review summarises recent advances and future direction of immunotherapy in patients with gastrointestinal malignancies.

Keywords: Adoptive cell therapy; Biliary; Checkpoint inhibition; Colorectal; Gastric; Gastrointestinal cancer; Hepatic; Immunotherapy; Oesophageal; Pancreatic; Review; Vaccine.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / administration & dosage
  • Cancer Vaccines / administration & dosage
  • Gastrointestinal Neoplasms / immunology
  • Gastrointestinal Neoplasms / therapy*
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy, Adoptive / methods
  • Randomized Controlled Trials as Topic

Substances

  • Antineoplastic Agents, Immunological
  • Cancer Vaccines